Erythropoietic agents/Lenalidomide Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

It is unknown what increases this risk.

What might happen:

You may be at a higher risk for blood clots in your arteries, veins and lungs, heart attack, and stroke when taking these two medicines together.

What you should do about this interaction:

If you experience shortness of breath, chest pain, or arm or leg swelling, contact your doctor immediately.If you experience chest pain, pain in your arms, neck, jaw or back, feeling sweaty, shortness of breath, or vomiting, contact your doctor immediately.If you experience sudden numbness or weakness, especially on one side of the body, headache or confusion, or problems with vision, speech, or balance, contact your doctor immediately.Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medication before checking with them first.

  • 1.Revlimid (lenalidomide) US prescribing information. Celgene Corporation May 2019.
  • 2.Aranesp (darbepoetin alfa) US prescribing information. Amgen Inc April 13, 2017.
  • 3.Streiff M, Holmstrom B, Ashrani Aetal. Cancer-associated venous thromboembolic disease. NCCN Clinical Practice Guidelines in Oncology. Available at www.nccn.org/professionals/physician_gls/f_guidelines.asp January, 2015.
  • 4.Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006 May 11;354(19):2079-80.
  • 5.Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008 Apr 1; 112(7):1522-8.
  • 6.Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, etal. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008 Feb;22(2):414-23.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.